Skip to content

Updates

Explore our latest insights, regulatory updates, and strategic reports for the life sciences sector.

Type
Blogs Testimonial
Sectors (2)
Agriculture Biotech Chemicals Cosmetics Diagnostics Digital Health Food and Feed Healthcare Medical Devices Pharmaceuticals
Expertises (1)
Advertising and Claims Commercial Contracts Corporate, Governance and Boardroom Counselling Data Protection, (Cyber)security and AI Due Diligence Environmental and Sustainability Financing and M&A Intellectual Property and Licensing Litigation Regulatory Compliance and Enforcement Spin-out and Starter Advisory Subsidies and Grants
Pharmaceuticals Remove filter Food and Feed Remove filter Intellectual Property and Licensing Remove filter Clear all

4 results

Newest first
Newest first Oldest first A–Z Z–A
Pharmaceuticals Commercial Contracts Intellectual Property and Licensing Testimonial

Axon supports pharmaceutical companies in licensing their products across Europe and beyond. We draft and negotiate licence agreements tailored to each market, helping clients maximise the value of their intellectual property.

Diagnostics Food and Feed Commercial Contracts Intellectual Property and Licensing Spin-out and Starter Advisory Testimonial

Axon assisted a start-up developing a real-time diagnostic test to define pathogens food. We negotiated and drafted an agreement with a university to support the further development & validation of the technology.

Biotech Food and Feed Commercial Contracts Intellectual Property and Licensing Testimonial

A Nordic company owns a proprietary technology for producing legume-based meat alternatives. Axon drafted technology licensing agreements and developed an IP strategy covering patents and trade secrets, with practical checklists for implementation.

Biotech Pharmaceuticals Commercial Contracts Intellectual Property and Licensing Testimonial

Axon advised a stock-listed biopharmaceutical company on antibody licensing and technology transfer agreements with two major US-based pharmaceutical companies. The deals involved the grant of commercial rights to the licensor's proprietary antibody platform technology.